Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Gemcitabine
100%
Bladder Cancer
100%
Nedaplatin
100%
Neutrophil
100%
Lymphocyte
100%
Chemotherapy
25%
Biological Marker
16%
Overall Survival
16%
Progression Free Survival
16%
Disease Exacerbation
8%
Sensitivity and Specificity
8%
Tumor Recurrence
8%
Kaplan Meier Method
8%
Tumor Progression
8%
Serositis
8%
Cancer Mortality
8%
Intensive Care
8%
Cystectomy
8%
Keyphrases
Gemcitabine
100%
Neutrophil-to-lymphocyte Ratio
100%
Nedaplatin
100%
Bladder Cancer Patients
100%
Chemotherapy
25%
Overall Survival
16%
Overall Mortality
16%
Advanced Bladder Cancer
16%
Disease Progression
8%
Cancer Mortality
8%
Tumor Recurrence
8%
Receiver Operating Characteristic Curve
8%
Progression-free Survival
8%
Response Predictors
8%
Radical Cystectomy
8%
Kaplan-Meier Analysis
8%
Tumor Progression
8%
Systemic Inflammatory Response
8%
Tumor Cancer
8%
Prognostic Impact
8%
Critical Care Patients
8%
Ratio Cut
8%
Median Progression-free Survival
8%
New Biomarkers
8%
Nursing and Health Professions
Bladder Cancer
100%
Gemcitabine
100%
Nedaplatin
100%
Neutrophil Lymphocyte Ratio
100%
Chemotherapy
25%
Biological Marker
16%
Overall Survival
16%
Progression Free Survival
16%
Disease Exacerbation
8%
Inflammation
8%
Intensive Care
8%
Sensitivity and Specificity
8%
Kaplan Meier Method
8%
Cancer Mortality
8%
Tumor Growth
8%
Cystectomy
8%
Tumor Recurrence
8%
Immunology and Microbiology
Neutrophil
100%
Lymphocyte
100%
Pretreatment
100%
Overall Survival
16%
Progression Free Survival
16%
Inflammation Response
8%
Cancer Mortality
8%
Biochemistry, Genetics and Molecular Biology
Neutrophil-To-Lymphocyte Ratio
100%
Gemcitabine
100%
Overall Survival
16%
Progression Free Survival
16%
Cancer Mortality
8%
Tumor Progression
8%